Showing results (121-130 of 305) with videos related to

Sort By:
Pageof 31
Oncotarget|August 19, 2015
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cellsMicol Rigoni, Chiara Riganti, Candida Vitale, et al.
Experimental Hematology|June 14, 2002
Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvestsMarco Ladetto, Paola Omedè, Selina Sametti, et al.
British Journal of Haematology|July 10, 2018
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinibElena Crisà, Daniela Cilloni, Elena M Elli, et al.
Experimental Hematology|March 24, 2007
Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoirAlberto Rocci, Irene Ricca, Chiara Dellacasa, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myelomaAntonio Palumbo, Ilaria Avonto, Benedetto Bruno, et al.
Haematologica|June 14, 2006
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantationBenedetto Bruno, Francesca Patriarca, Roberto Sorasio, et al.
Blood|December 7, 2006
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myelomaAntonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, et al.
Tumori|December 12, 2013
Cost of illness in patients with multiple myeloma in Italy: the CoMiM studyMaria Teresa Petrucci, Elisabetta Calabrese, Anna Levi, et al.
Current Drug Targets|August 12, 2009
First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspectivePellegrino Musto, Fiorella D'Auria, Giuseppe Pietrantuono, et al.
Annals of Hematology|January 4, 2021
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myelomaStefania Oliva, Lorenzo De Paoli, Marina Ruggeri, et al.
Pageof 31